Leflunopharm (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, a key step in pyrimidine synthesis. By limiting the production of pyrimidines, it suppresses the proliferation of activated lymphocytes, thereby dampening the autoimmune response that drives joint inflammation.

The specific dose of Leflunopharm is determined by the prescribing physician based on the patient’s clinical condition, response, and safety parameters. Dosage adjustments are made according to individual therapeutic needs and laboratory monitoring.

Leflunopharm is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional DMARDs such as methotrexate, leflunomide offers a once‑daily oral regimen and a distinct mechanism targeting pyrimidine synthesis. It may be chosen when patients cannot tolerate methotrexate or need an alternative therapeutic pathway, though safety profiles differ and must be evaluated individually.

Leflunopharm should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Leflunopharm is taken orally, usually as a single tablet once daily with or without food, as directed by the prescriber. Swallow the tablet whole and do not crush or split it unless specifically instructed.

The most serious risks include severe liver injury, life‑threatening infections, pulmonary toxicity, bone‑marrow suppression, and teratogenic effects. Patients should be monitored regularly for liver function, blood counts, and respiratory symptoms, and the drug must be stopped immediately if serious adverse events occur.

Leflunopharm is contraindicated in pregnant women, patients with severe liver disease, uncontrolled infections, or known hypersensitivity to leflunomide. It should also be avoided in individuals planning pregnancy unless an effective contraception method is in place throughout treatment and for a defined wash‑out period after discontinuation.